Phase 2 N=9 Treatment of Oral Premalignant Lesions With 5-ALA PDT
Leukoplakia · Erythroplakia
Primary: Maximum Tolerated Dose — 8 J/cm2
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=132 Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia
Lip and Oral Cavity Cancer · Oral Leukoplakia · Oropharyngeal Cancer
Primary: Relative Percent Change in Total Lesion Area After 6 Months on Study — -20.6; -17.1 percentage change
Phase 2 N=33 Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia
Leukoplakia, Oral
Primary: Best Overall Response Rate (BORR) — 36.4 percentage of participants
Phase 2 N=21 Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia
Head and Neck Cancer · Oral Leukoplakia
Primary: Patients' Overall Response — 0; 15; 2; 4 Participants
Phase 2 N=21 Pimecrolimus Cream for Oral Lichen Planus
Oral Lichen Planus
Primary: The Primary Efficacy Variable Was the Change in the Investigator's Global Assessment of the Overall Severity of Disease From Baseline to Week 6. — 2.4; 2.45; 1.6; 2.27…
Phase 2 N=59 Treatment of Oral Warts in HIV+ Patients
Papillomatosis · HIV Infections
Primary: Change in Total Oral Mucosal Area Covered by Warts. — 11; 2 participants — p=0.30
Phase 2 N=41 Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention
Squamous Cell Carcinoma of Mouth · Intraepithelial Neoplasia
Primary: Light Microscopic Histologically Scored Diagnoses Pretreatment to Post Treatment — 2.36; 2.83; 1.9; 2.58 unit on histologic grade scale — p=0.048
N/A N=93 Methylation of p16 CpG Island And Malignant Transformation of Oral Epithelial Dysplasia
Oral Epithelial Dysplasia, Mild or Moderate Grade
Primary: The Number of Participants With Both Clinical and Histological Evidence of Malignant Transformation of Oral Epithelial Dysplasia — 32; 46 participants
N/A N=27 Comparison or Rose Bengal and Toluidine Blue Staining for Lesion Detection Efficacy
Oral Leukoplakia · Oral Lichen Planus · Premalignant Lesion
Primary: Number and Percentage of Lesions That Were Stained Positive — 29; 28 lesions — p=0.005
Phase 3 N=928 Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity
Squamous Cell Carcinoma of the Oral Cavity · Squamous Cell Carcinoma of the Soft Palate
Primary: Overall Survival (OS) — 46.3; 58.1; 52.9 months — p=0.4051
N/A N=78 Salivary and Serum Leptin Levels in Oral Lichen Planus Patients: A Case-control Study.
Oral Lichen Planus · Leptin Levels
Primary: Serum Leptin Level — 13.23; 4.20 ng/ml
Phase 2 N=15 Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia
Oral Cavity Carcinoma · Oral Intraepithelial Neoplasia
Primary: Oral Cancer-free Survival — NA; 6.7 Months
Phase 1 N=100 Oral Mucosal Effects In Adult Smokers Associated With Two Nicotine Lozenge Formulations
Safety Issues
Primary: OMI-20 Total Score Change From Baseline to Day 3 — 0.0; 0.0 score on a scale
Phase 2 N=20 A Clinical Study of Curcuminoids in the Treatment of Oral Lichen Planus
Oral Lichen Planus
Primary: Percent Change From Baseline to Two Weeks in Symptoms and Signs of Oral Lichen Planus (OLP) — -22; 0; -17; 0 percent change
Phase 3 N=40 Evaluation of Green Tea as Antioxidant Agent in Management of Oral Lichen Planus
Oral Lichen Planus
Primary: Pain — 0; 4; 4.4 units on a scale
Early Phase 1 N=18 Using MASL to Combat Oral Cancer
Squamous Cell Carcinoma of Head and Neck
Primary: Pre-treatment OSCC Morphology and PDPN Expression — 2.8; 3.4; 2.5 score on a scale from 1 to 5 — p=<0.05
Phase 2 N=5 A Study of Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy and Concurrent Chemotherapy
Mucositis · Head and Neck Cancer
Primary: Number of Participants With Adverse Events (AEs) — 2; 3; 0; 2 participants
N/A N=63 A Randomized Study of Sulindac in Oral Premalignant Lesions
Leukoplakia, Oral · Benign Neoplasms
Primary: - To Evaluate the Efficacy of Sulindac in Subjects With Early or Advanced Oral Premalignant Lesion (OPL) by Both Clinical Response (Reduction in Size of All Lesions) and…
Phase 2 N=24 Dexamethasone Solution for the Treatment of Oral Lichen Planus
Lichen Planus
Primary: Change in Oral Sensitivity — -4.5; -6.0 score on a scale
Phase 3 N=94 Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients
Squamous Cell Carcinoma of Nasopharynx · Squamous Cell Carcinoma of Oropharynx · Squamous Cell Carcinoma of Hypopharynx
Primary: Incidence and / or Severity of Oral Mucositis — 19; 3 Grade 3-4 oral mucositis — p=0.05
Phase 4 N=28 A Clinical Trial to Study the Effects of Two Drugs, Lycopene and Prednisolone in Patients With Oral Lichen Planus
Oral Lichen Planus
Primary: Change in Severity of Lesions(Degree of Reticular, Erythematous and Ulceration) by Using Piboonniyom REU Severity Score — 2.15; 0.73 Scores on a scale — p=0.004
Phase 2 N=68 Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma
Oral Squamous Cell Carcinoma
Primary: Pathologic Response. — 25; 2; 4; 4 Participants
Phase 2 N=30 Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral Cancer Cancer.
Oral Cancer
Primary: Number of Participants With no Residual Tumor Following Photodynamic Therapy (PDT) — 22 Participants
Phase 3 N=303 Erlotinib Prevention of Oral Cancer (EPOC)
Oral Cancer
Primary: Oral Cancer-free Survival in Participants Receiving Erlotinib as Compared With the Control Arm or Placebo Group. — 55; 18 Participants
N/A N=281 Oral Cell DNA Adducts in Smokers
Lung Cancer
Primary: Concentration of γ-OH-Acr-dGuo, a Major Acrolein-DNA Adduct — 49.7; 67.1; 46.5 10^9 nucleotides/mL
Phase 3 N=23 Use of Topical NSAID to Reduce Pain in Oral Lichen Planus and Oral Lichenoid Lesions.
Oral Lichen Planus · Oral Lichenoid Mucositis · Oral Lichenoid Reaction
Primary: Self-reported Pain Scores Using 100m Visual Analog Scale 0-100 Pain Score. — 6.4; 12.3 mm
Phase 4 N=20 Photodynamic Therapy (PDT) With Levulan and Blue Light for the Treatment of Actinic Cheilitis
Actinic Cheilitis
Primary: Number of Participants With a Change in Clearance From Baseline — 1; 1; 9; 4 Participants
Early Phase 1 N=16 Neoadjuvant Imiquimod Immunotherapy for Oral Cancer
Oral Squamous Cell Carcinoma
Primary: Number of Participants With 50% Reduction in Tumor Cell Count and Major Pathologic Response — 9; 6 Participants
Phase 2 N=10 Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma
Oral Squamous Cell Carcinoma
Primary: Determine an Efficacious Dose (mg/cm2) of PRV111 (Cisplatin Transmucosal System) Via Number of Tumor Responses — 7 Participants
Phase 2 N=86 Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer
Advanced Breast Cancer
Primary: Number of Participants With Stomatitis Grade ≥ 2 — 2; 83; 1 Participants — p=<0.001